Agios Pharmaceuticals, Inc.
AGIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001439222
In the last 90 days, Agios Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 238 institutions reported holding it in 13F filings for Q2 2026, worth $2.45B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Agios Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 1 insider, $1.06M in total
- Insiders trading
- 1
- Net value
- −$1.06M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Agios Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | 54,645 | Aug 6, 2026 | 9 |
| Backstrom Jay T. | Director | 1,447 | Jul 10, 2026 | 2 |
| Capello Jeffrey D | Director | 10,865 | Jun 23, 2026 | 2 |
| Foster-Cheek Kaye I | Director | 10,284 | Jun 23, 2026 | 1 |
| Fouse Jacqualyn A | Director | 154,156 | Jun 23, 2026 | 1 |
| Goff Brian | Chief Executive Officer | 184,508 | Jun 23, 2026 | 4 |
| Smith Cynthia | Director | 15,230 | Jun 23, 2026 | 1 |
| Ho Maykin | Director | 19,848 | Jun 23, 2026 | 1 |
| Scadden David | Director | 20,419 | Jun 23, 2026 | 4 |
| Ballal Rahul D. | Director | 15,230 | Jun 23, 2026 | 1 |
| Owen Catherine E. | Director | 10,865 | Jun 23, 2026 | 2 |
| Jones Cecilia | Chief Financial Officer | 54,998 | Jun 23, 2026 | 5 |
| Burns James William | Chief Legal Officer | 49,306 | Jun 23, 2026 | 4 |
| Milanova Tsveta | Chief Commercial Officer | 46,829 | Jun 23, 2026 | 5 |
| Viswanadhan Krishnan | Chief Strategy and Operations | 10,282 | Jun 23, 2026 | 4 |
| Washburn Theodore James Jr. | Principal Accounting Officer | 868 | Mar 5, 2026 | 2 |
| Schenkein David P | Director | 126,242 | Jun 24, 2024 | 0 |
| Poddar Richa | Chief Commercial Officer | 8,508 | Oct 18, 2022 | 0 |
| Maraganore John | Director | 30,028 | Jun 23, 2022 | 0 |
| Clancy Paul J | Director | 6,549 | Jun 23, 2022 | 0 |
| Clark Ian T | Director | 6,549 | May 24, 2022 | 0 |
| Biller Jonathan | Chief Financial Officer | 22,953 | Mar 3, 2022 | 0 |
| Car Bruce | Chief Scientific Officer | 16,752 | Mar 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Viswanadhan KrishnanChief Corp Dev & Strategy | SSale | −2.96K | $27.80 | −$82.3K | −36.5%5.14K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Goff BrianChief Executive Officer | SSale | −19.1K | $34.71 | −$661.9K | −9.4%184.5K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Viswanadhan KrishnanChief Corp Dev & Strategy | SSale | −2.96K | $34.71 | −$102.7K | −22.3%10.3K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Milanova TsvetaChief Commercial Officer | SSale | −3.26K | $34.71 | −$113.2K | −6.5%46.8K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Jones CeciliaChief Financial Officer | SSale | −3.14K | $34.71 | −$109.0K | −5.4%55.0K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Gheuens SarahChief Medical Officer | SSale | −2.94K | $34.71 | −$102.0K | −3.5%80.3K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Burns James WilliamChief Legal Officer | SSale | −3.28K | $34.71 | −$113.8K | −6.2%49.3K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:03 PM ET | Jul 1 | 1 day | Gheuens SarahChief Medical Officer | SSale | −4.01K | $37.56 | −$150.5K | −4.5%84.6K after | 10b5-1 |
| Aug 6, 2026 (view filing)4:13 PM ET | Aug 4 | 2 days | Gheuens SarahChief Medical Officer | SSale | −30.0K | $30.48 | −$914.4K | −35.4%54.6K after | 10b5-1 |